NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
14d
Clinical Trials Arena on MSNBiohaven’s pivotal bipolar drug trial fails, stock takes hitBiohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking ...
Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its ...
Highlights,Institutional investments in Biohaven Ltd. have shown recent increases.,The company focuses on developing ...
13d
Investor's Business Daily on MSNBiohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion OpportunityBiohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.Analysts called the stock reaction overdone, while Chief Executive Vlad Coric ...
Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. | Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial.
Biohaven has a 1 year low of $26.80 and a 1 year high of $60.46. The stock’s 50-day simple moving average is $37.06 and its 200-day simple moving average is $42.08.
Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range ...
Biohaven Ltd. (NYSE:BHVN – Get Free Report) fell 6.1% during mid-day trading on Monday after the company announced weaker ...
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differentiating Biohaven's new small-molecule class of degraders from the monoclonal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results